Intranasal Therapeutics, Inc. (ITI)

10 articles about Intranasal Therapeutics, Inc. (ITI)

• Intranasal Therapeutics, Inc. (ITI) Changes Name to Ikano Therapeutics and Completes $9 Million Series B Financing

  3/2/2009

• Intranasal Therapeutics, Inc. (ITI) Names Jeffrey Edelson, MD, Executive Vice President, R&D and Chief Medical Officer

  7/8/2008

• Intranasal Therapeutics, Inc. (ITI) Names Vice Presidents of Pharmaceutical Development and Commercial Development

  11/15/2007

• Intranasal Therapeutics, Inc. (ITI) Adds Key Executives To Management Team

  12/6/2006

• Intranasal Therapeutics, Inc. (ITI) Closes $39.1 Million Series A Venture Financing; Company To Advance Clinical Programs In Areas Of Pain Management And Central Nervous System Conditions

  8/15/2006

• New Intranasal Therapeutics, Inc. (ITI) Study Shows Potential Of Intranasal Midazolam As An Effective, Noninvasive Sedative

  7/26/2006

• Intranasal Therapeutics, Inc. (ITI) Announces Formation Of Scientific Advisory Board Led By The Dean Of The University of Iowa's College of Pharmacy

  1/25/2006

• Intranasal Therapeutics, Inc. (ITI) Announces Appointment Of Timothy I. Mitchell As Vice President Of Quality And Regulatory Affairs

  1/20/2006

• Intranasal Therapeutics, Inc. (ITI) Announces Patent Request Filing For THC Nasal Spray

  10/25/2005

• ITI Announces U.S. Patent Approval For Multiple Dose Delivery Device

  10/13/2005